1. Home
  2. ABBV
  3. ABBV News

Latest AbbVie Inc. (ABBV) News on November 23, 2024

AbbVie gains on Leerink Partners upgrade to Outperform
ABBV

Yahoo Finance Video

12 hours ago

AbbVie gains on Leerink Partners upgrade to Outperform

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback
ABBV

Investor's Business Daily

12 hours ago

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

ABBV

MT Newswires

13 hours ago

AbbVie Shares Rise as Leerink Partners Upgrades Stock

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
ABBV

Pharmaceutical Technology

16 hours ago

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

ABBV

MT Newswires

a day ago

Leerink Partners Upgrades AbbVie to Outperform From Market Perform, Price Target is $206

AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
ABBV

Simply Wall St.

2 days ago

AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
ABBV

Zacks

3 days ago

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
ABBV

Zacks

4 days ago

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap

Where Will AbbVie Be in 5 Years?
ABBV

Motley Fool

4 days ago

Where Will AbbVie Be in 5 Years?

RVPH: Year-End OLE Update
ABBV

Zacks Small Cap Research

4 days ago

RVPH: Year-End OLE Update

What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
ABBV

Pharma Voice

4 days ago

What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine

ABBV

MT Newswires

5 days ago

Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating

AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
ABBV

Zacks

5 days ago

AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
ABBV

PR Newswire

5 days ago

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products

ABBV

MT Newswires

5 days ago

Aldeyra Therapeutics' Resubmitted Marketing Application for Eye Disease Drug Accepted by FDA

AbbVie’s Elahere wins European approval for certain ovarian cancers
ABBV

Pharmaceutical Technology

5 days ago

AbbVie’s Elahere wins European approval for certain ovarian cancers

Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
ABBV

Motley Fool

5 days ago

Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip

ABBV

MT Newswires

5 days ago

AbbVie Says Elahere Gets Approval From European Commission as Ovarian Cancer Treatment

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
ABBV

PR Newswire

5 days ago

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

ABBV

Morningstar Research

5 days ago

Analyst Report: AbbVie Inc.

AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
ABBV

Simply Wall St.

6 days ago

AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year

Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment
ABBV

Insider Monkey

7 days ago

Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment

Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
ABBV

Zacks

8 days ago

Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

ABBV

MT Newswires

8 days ago

Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating

AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
ABBV

Zacks

8 days ago

AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
ABBV

Motley Fool

8 days ago

Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock

Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV
ABBV

GuruFocus.com

8 days ago

Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
ABBV

Zacks

9 days ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

2 Dividend Stocks to Buy Hand Over Fist in November
ABBV

Motley Fool

9 days ago

2 Dividend Stocks to Buy Hand Over Fist in November

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
ABBV

PR Newswire

9 days ago

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations

ABBV

MT Newswires

9 days ago

Deutsche Bank Adjusts Price Target on AbbVie to $177 From $180, Keeps Hold Rating

ABBV

MT Newswires

10 days ago

JPMorgan Adjusts Price Target on AbbVie to $200 From $210, Keeps Overweight Rating

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
ABBV

Benzinga

11 days ago

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

ABBV

MT Newswires

11 days ago

UBS Lowers Price Target on AbbVie to $181 From $200, Keeps Neutral Rating

AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
ABBV

Zacks

11 days ago

AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains

AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials
ABBV

Clinical Trials Arena

11 days ago

AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials

ABBV

MT Newswires

11 days ago

Goldman Sachs Cuts AbbVie Price Target to $205 From $210, Maintains Buy Rating

Some Investors May Be Willing To Look Past AbbVie's (NYSE:ABBV) Soft Earnings
ABBV

Simply Wall St.

11 days ago

Some Investors May Be Willing To Look Past AbbVie's (NYSE:ABBV) Soft Earnings

Company News for Nov 12, 2024
ABBV

Zacks

11 days ago

Company News for Nov 12, 2024

What the NFL Draft Can Teach Investors About Big Pharma
ABBV

The Wall Street Journal

11 days ago

What the NFL Draft Can Teach Investors About Big Pharma

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'
ABBV

Investor's Business Daily

12 days ago

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

AbbVie tumbles on drug test disappointment, Bristol-Myers gains
ABBV

Yahoo Finance Video

12 days ago

AbbVie tumbles on drug test disappointment, Bristol-Myers gains

Why AbbVie Stock Was Getting Mashed on Monday
ABBV

Motley Fool

12 days ago

Why AbbVie Stock Was Getting Mashed on Monday

ABBV

MT Newswires

12 days ago

Top Midday Decliners

ABBV

MT Newswires

12 days ago

Sector Update: Health Care Stocks Decline Monday Afternoon

ABBV

MT Newswires

12 days ago

Sector Update: Health Care

ABBV

MT Newswires

12 days ago

Raymond James Cuts AbbVie Price Target to $218 From $221

AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
ABBV

Benzinga

12 days ago

AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated

ABBV

MT Newswires

12 days ago

AbbVie Says Phase 2 Trials of Emraclidine in Schizophrenia Fail to Meet Primary Endpoints

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
ABBV

Investor's Business Daily

12 days ago

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails

ABBV

Investing.com

12 days ago

AbbVie shares slip after schizophrenia drug trial misses primary endpoint

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
ABBV

PR Newswire

12 days ago

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

ABBV

Argus Research

12 days ago

Weekly Stock List

Dividend Investor Who Started 'Homeless and Penniless' Now Earns $4,800 a Month, Reveals Top 5 Stock Holdings
ABBV

Benzinga

13 days ago

Dividend Investor Who Started 'Homeless and Penniless' Now Earns $4,800 a Month, Reveals Top 5 Stock Holdings

3 Spectacular High-Yield Dividend Stocks to Buy in November
ABBV

Motley Fool

13 days ago

3 Spectacular High-Yield Dividend Stocks to Buy in November

Investing in AbbVie (NYSE:ABBV) five years ago would have delivered you a 179% gain
ABBV

Simply Wall St.

14 days ago

Investing in AbbVie (NYSE:ABBV) five years ago would have delivered you a 179% gain

My Favorite Dividend King to Buy in November
ABBV

Motley Fool

14 days ago

My Favorite Dividend King to Buy in November

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
ABBV

Zacks

15 days ago

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?

ABBV

Morningstar Research

15 days ago

Analyst Report: AbbVie Inc.

Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
ABBV

Zacks

15 days ago

Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?

Zacks Investment Ideas feature highlights: AbbVie, Visa and Comfort Systems USA
ABBV

Zacks

15 days ago

Zacks Investment Ideas feature highlights: AbbVie, Visa and Comfort Systems USA

2 Dividend Kings That Would Have Doubled Your Money in 5 Years
ABBV

Motley Fool

15 days ago

2 Dividend Kings That Would Have Doubled Your Money in 5 Years

Dividend Watch: Three Companies Boosting Quarterly Payouts
ABBV

Zacks

15 days ago

Dividend Watch: Three Companies Boosting Quarterly Payouts

RHHBY or ABBV: Which Is the Better Value Stock Right Now?
ABBV

Zacks

16 days ago

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
ABBV

PR Newswire

16 days ago

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

ABBV

Argus Research

16 days ago

October Resets Economic, Interest Rate Expectations

ABBV

Argus Research

16 days ago

Daily Spotlight: Value Sectors

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
ABBV

Pharmaceutical Technology

17 days ago

Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

ABBV

MT Newswires

17 days ago

HSBC Adjusts Price Target on AbbVie to $230 From $215, Maintains Buy Rating

ABBV

MT Newswires

17 days ago

Guggenheim Adjusts Price Target on AbbVie to $221 From $212, Maintains Buy Rating

ABBV

MT Newswires

18 days ago

Daiwa Securities Adjusts AbbVie Price Target to $210 From $190

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
ABBV

Zacks

18 days ago

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

ABBV

MT Newswires

18 days ago

Deutsche Bank Adjusts AbbVie Price Target to $180 From $175, Maintains Hold Rating

Should We Be Delighted With AbbVie Inc.'s (NYSE:ABBV) ROE Of 75%?
ABBV

Simply Wall St.

18 days ago

Should We Be Delighted With AbbVie Inc.'s (NYSE:ABBV) ROE Of 75%?

Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
ABBV

GuruFocus.com

18 days ago

Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight

Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
ABBV

Insider Monkey

18 days ago

Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?

ABBV

MT Newswires

19 days ago

Argus Upgrades AbbVie to Buy From Hold, Price Target is $220

ABBV

Argus Research

19 days ago

Analyst Report: AbbVie Inc

ABBV

Argus Research

19 days ago

Market Digest: THRM, DINO, KLAC, OKE, RJF, SYK, META, ABBV, NCLH

58-Year-Old Retiree Living Off Dividends Shares His Portfolio: Top 12 Stocks, ETFs
ABBV

Benzinga

21 days ago

58-Year-Old Retiree Living Off Dividends Shares His Portfolio: Top 12 Stocks, ETFs

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
ABBV

Investor's Business Daily

22 days ago

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
ABBV

Zacks

22 days ago

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus

ABBV

MT Newswires

22 days ago

Goldman Sachs Raises Price Target on AbbVie to $210 From $208

AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
ABBV

Simply Wall St.

22 days ago

AbbVie Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

AbbVie and EvolveImmune Therapeutics sign oncology collaboration
ABBV

Pharmaceutical Technology

22 days ago

AbbVie and EvolveImmune Therapeutics sign oncology collaboration

5 Stocks That Recently Announced Dividend Hikes
ABBV

Zacks

22 days ago

5 Stocks That Recently Announced Dividend Hikes

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
ABBV

BioPharma Dive

22 days ago

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
ABBV

Quartz

22 days ago

Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up

AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday
ABBV

Barrons.com

23 days ago

AbbVie’s Deal for Alzheimer’s Antibody Raises Curtain for Roche News on Wednesday

ABBV

MT Newswires

23 days ago

UBS Adjusts Price Target on AbbVie to $200 From $195, Maintains Neutral Rating

ABBV

MT Newswires

23 days ago

AbbVie to Collaborate With EvolveImmune Therapeutics For Development of Cancer Biotherapeutics

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
ABBV

GlobeNewswire

23 days ago

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

AbbVie announces 2025 dividend increase of 5.8% to $1.64 from $1.55 per share
ABBV

TipRanks

23 days ago

AbbVie announces 2025 dividend increase of 5.8% to $1.64 from $1.55 per share

ABBV

MT Newswires

23 days ago

Raymond James Adjusts Price Target on AbbVie to $221 From $200, Maintains Outperform Rating

ABBV

MT Newswires

23 days ago

BMO Capital Adjusts Price Target on AbbVie to $228 From $220, Maintains Outperform Rating

ABBV

MT Newswires

23 days ago

Piper Sandler Adjusts Price Target on AbbVie to $212 From $209, Maintains Overweight Rating

ABBV

MT Newswires

23 days ago

Cantor Fitzgerald Adjusts Price Target on AbbVie to $240 From $200, Maintains Overweight Rating

ABBV

MT Newswires

23 days ago

Citigroup Adjusts Price Target on AbbVie to $226 From $215, Maintains Buy Rating

ABBV

MT Newswires

23 days ago

Morgan Stanley Raises Price Target on AbbVie to $231 From $218, Keeps Overweight Rating

ABBV

Thomson Reuters StreetEvents

23 days ago

Q3 2024 AbbVie Inc Earnings Call

Share on Social Networks: